The schematic model of the human oxytocin receptor with marked amino-acid residues that are putatively involved in ligand-binding All of these receptors have the ability to bind AVP and/or OT with different affinities. Because OT system activation was observed in fetal and newborn hearts at a stage of intense cardiac hyperplasia (Jankowski et al., 2004) , we hypothesized a role for OT in cardiomyocyte (CM) differentiation. The initial experiments demonstrated that OT induces CM differentiation of the mouse embryonal carcinoma (EC) P19 cell line, a common stem cell model for studying early heart differentiation (Paquin et al., 2002) . Then, several studies attempted to understand the mechanisms of cardiac differentiation by OT. Stimulation of CM differentiation can be concomitant with neovascularization because OT stimulates endothelial cells growth and angiogenesis. In pathological conditions such as cardiac ischemia and diabetes this inducer can be used to stimulate production of lost cardiac cells. The advantage of this therapy is supported by the fact that OT is endogenously produced in the organism, and does not have significant side effects when used in clinics. Moreover, it is now possible to inject (transplant) one's own stem cells after previous stimulation with OT inducers, as in the case of a heart infarct. Alternatively, direct treatment with OT molecules could promote cardiomyogenesis in situ and regeneration of a damaged heart.
OT induces stem cell differentiation
The manipulations of OT, during the perinat a l p e r i o d h a v e b e c o m e a n a c c e p t e d -b ut largely unstudied-aspect of human development. For example, synthetic OT is used to induce childbirth (Dudley, 1997) . In cases of premature delivery, the OT antagonist (OTA) is used for slowing or preventing labor (Husslein, 2002) . Although such complex manipulations are routine in modern obstetrics, little is known on the possible cellular and developmental consequences of these treatments. Several studies have proposed a role for OT as a growth and differentiation/maturation factor in a gestational/perinatal context. In the mother, OT is required for postpartum alveolar proliferation, and it induces differentiation and proliferation of myoepithelial cells in the mammary gland necessary for milk ejection (Gimpl & Fahrenholz, 2001) . The OT/OTR system is expressed in human cumulus/luteal cells surrounding oocytes, and weak OTR gene expression is even observed in oocytes (Furuya et al., 1995) . Moreover, when fertilized mouse oocytes are cultured with OT in vitro, they develop into the blastocyst stage at a higher rate than their unstimulated counterparts (Furuya, et al., 1995) . On the other hand, hormonal treatment may, in its simplest form, induce mammalian stem cells into a special cell type that retains the ability to self-renew (i.e. undergo cell division in an undifferentiated state) indefinitely and to differentiate into specialized cells. In this regard, it has been suggested that OT plays a role in bone homeostasis and osteoporosis based on the proliferative effects of OT on osteoblasts in vitro and the modulation of blood parameters associated with bone formation in normal rats (Petersson et al., 2002b) . Recently, OT has been implicated in the regulation of the osteoblast/adipocyte balance of human multipotent adipose-derived stem cells and human bone marrow mesenchymal stromal cells (Elabd et al., 2008) . Our interest in the cardiac OT system emerged from long time investigations into the role of the brain in the control of cardio-renal homeostasis (Gutkowska & Jankowski, 2008; Gutkowska et al., 2000; McCann et al., 2002) . These experiments led to the observations that OT and its receptor (OTR) are synthesized in the human and rat heart Jankowski et al., 1998) and that OT exerts cardio-protection either directly or via stimulation of mediators such as the natriuretic peptides (NPs) Gutkowska et al., 2000) and nitric oxide (NO) . Since the study showing that OT induces differentiation of EC P19 cells into the functional cardiac muscle (Paquin et al., 2002) , several reports have confirmed OT-stimulated cardiomyogenesis in different lines of embryonic stem cells (Fathi et al., 2009; Gassanov et al., 2008a; Hatami et al., 2007; Jankowski et al., 2004; Stefanidis et al., 2009; Uchida et al., 2007) . In fact, OT can be considered as an established myogenic morphogen (Breton et al., 2002) . It induces 540 differentiation of myoepithelial cells in the mammary gland (Sapino et al., 1993) . The skeletal myocytes generation has also been observed in OT-induced cardiomyogenesis as well as adipogenesis (Bouchard & Paquin, 2009) . OT increases the rate of myoblast fusion and myotubule formation (Breton et al., 2001) . Interestingly, most transcription factors identified so far in the heart are also present in other muscle cells, and myoblast transplantation to the injured heart improves regional systolic heart function (Thompson et al., 2003) . Assuming similarities in the differentiation mechanisms of skeletal and cardiac muscles and the expression of both OT and OTR in these cells (Breton et al., 2001; Jankowski et al., 1998) , we can speculate that OT plays a role in cardiac muscle regeneration.
OT stimulates CM differentiation in 3-dimensional cultures of stem cells
EC P19 cells are derived from a teratocarcinoma in CH3/He mice and can differentiate into all 3 germ layers (van der Heyden & Defize, 2003) . Developmentally, pluripotent EC P19 cells appear to differentiate by the same mechanisms as normal embryonic stem cells (McBurney, 1993) . Culture and differentiation of the cells is simple and cells remain undifferentiated without the help of feeder cells or inhibitory factors, and unlike embryonic ES cells, they do not spontaneously generate cardiomyocytes. The efficient differentiation of EC P19 cells depends on the prior formation of non-adhering cell aggregates (van der Heyden & Defize, 2003) . Traditionally, cell aggregates formation in suspension culture under 0.5-1.0% dimethyl sulfoxide (DMSO) has been used to induce cardiomyocyte differentiation of EC P19 cells (McBurney, 1993) . Efficiency of cardiac differentiation of ES and EC P19 cells in vitro is still not optimal in response to various agents, with yields varying between 5% and 20% of cardiomyocytes Gassanov et al., 2008a; Gassanov et al., 2008b; Gassanov et al., 2007; Paquin et al., 2002) . In the EC P19 model, the order of cardiomyogenesis efficiency was OT (10 −7 M) ≥ DMSO >retinoic acid (10 −8 -10− 7 M) when these agents were added to cultures during the entire period of cell aggregation Jankowski et al., 2004; Paquin et al., 2002) . It is noteworthy that exposure of EC P19 cells to higher retinoic acid concentration (10 −6 M) over the aggregation period generates neurons but not muscle cells. The presence of OT significantly influences the shape and size of aggregated stem cells isolated from the rat heart ). This suggests that conditions inside aggregates, such as hypoxia, promote OTR and OT expression. Indeed, hypoxia can influence the functionality of OTR in cardiac cells and mechanism of natriuretic peptides secretion in response to OT treatments (Hopkins et al., 2004) . Our data indicate that OT increases glucose uptake by CMs exposed to chemical hypoxia (Florian et al., 2010) . Multicellular complex aggregate formation and exposure to various agents promotes generation of mesodermal or ectodermal lineages. In embryonic D3 stem cells, spontaneously producing beating cell colonies upon aggregation, the mesodermal derivatives formed in embryoid bodies (EB) include subtypes of cardiac cells (atrial CMs, ventricular CMs and pacemaker cells) which are potently enhanced by treatment with OT as identified by histological, molecular, and electrophysiological criteria (Gassanov et al., 2008a) . However, molecular events occurring during aggregation and the necessity of their aggregation for differentiation are not entirely understood. High cell densities can at least trigger spontaneous differentiation from EC P19 cells (McBurney, 1993) . Skerjanc et al. have reported that overexpression of Nkx2.5 can induce cardiomyogenesis in aggregated EC P19 cells, but not when they are maintained in monolayer cultures (Skerjanc et al., 1998) . On the other hand, the addition of soluble bone morphogenic protein 4 (BMP 4) into the culture media resulted in the requirement for cell aggregation and induced cardiac differentiation being bypassed in monolayer cultures of EC P19 cells overexpressing Nkx2.5 (Jamali et al., 2001 ). This result demonstrated that cell aggregation is crucial for the generation of the BMP 4 signal in EC P19 cells. EC P19Cl6 cells derived from EC P19 cells seem not to be committed to a mesodermal lineage but rather represent a stage closer to differentiated cardiac muscle than the parental cell line. It was recently observed that OT does not induce cardiomyogenesis in monolayers of EC P19Cl6 cells, but does so in aggregates (Uchida et al., 2007) . The same authors suggested that OT-induced cardiac differentiation is not mediated by the expression of BMP 4 signaling molecules because the induction of BMP 4 signaling cascade can bypass the requirement for prior EB formation (Fathi et al., 2009 ).
OT molecular forms of OT stimulating differentiation
OT, recognized as a female reproductive hormone, is largely produced in hypothalamic magnocellular neurons of paraventricular and supraoptic nuclei. Biochemical and recombinant DNA studies have demonstrated that it is synthesized as a non-glycosylated protein, which undergoes an initial endoproteolytic cleavage by the convertase magnolysin (EC 3.4.24.62) to OT-Gly-Lys-Arg (OT-GKR) (Brownstein et al., 1980; Burbach et al., 2001) . Subsequent processing produces other OT extended molecules: OT-Gly-Lys (OT-GK) and OT-Gly (OT-G) (Burbach et al., 2001 ), all these forms are often referred to as OT-X (Morris et al., 1992) . OT-G is converted by an -amidating enzyme to C-amidated nonapeptide. OT is released into the bloodstream in this form. OT-X forms have been detected in the developing brain of animals and in fetal plasma. In rats, enzymatic OT-X conversion to OT is almost complete in adulthood, but not in fetuses, which accumulate OT-X in the brain (Altstein et al., 1988a; Altstein & Gainer, 1988b . Similarly, the plasma OT-X elevation reported during early fetal development in sheep (Morris et al., 1992 ) is reduced in late gestation, when OT begins to predominate in the cbloodstream. We have recently shown that the OT-GKR is the main form in the fetal heart. This attracted our attention because estrogen-mediated BP reduction in humans is associated with elevated plasma OT-GKR but not OT, indicating greater bioactivity and stability of this form (Light et al., 2005) . We have also found that OT-GKR even more potently than OT mediates cardiomyogenesis in EC P19 cells (Jankowski et al., 2004) and D3 stem cells (Gassanov et al., 2008a) . The patch-clamp analysis indicates that OT-GKR differentiates D3 cells into CMs of the ventricular phenotype and reduces formation of pacemaker cells (Gassanov et al., 2008a) . Furthermore, OT-GKR significantly increases glucose uptake in CM exposed to hypoxia (Florian et al., 2010) . To determine whether the genetic modification of stem cells also stimulates cardiomyogenesis, the OT-Gly-Lys-Arg gene was inserted into D3 stem cells. In effect, we observed stimulation of spontaneously-beating embryoid bodies and predominant stimulation of cells expressing the ventricular electrophenotype and molecular CM markers (Gassanov et al., 2008a) . Interestingly, the elongated form of OT, OT-Gly-Lys-Arg, was the most potent cardiomyogen of all the OT-like molecules investigated. These findings provide a new strategy for the regeneration of diseased hearts. Transgenic cells producing OT-GlyLys-Arg can be injected, for cardioprotection, into the myocardial infarcted rat model. Analysis of cardiac remodeling, scar reduction, hemodynamic and echographic parameters www.intechopen.com Embryonic Stem Cells: The Hormonal Regulation of Pluripotency and Embryogenesis 542 together with histochemical and molecular analyses will provide answers as to whether these treatments can stimulate cardioprotection.
Mechanism in OT-induced stem cell differentiation
Some preliminary observations point to a mechanism involved in this process. Ca +2 mobilization in response to OT treatment has been detected in D3 ES cells differentiating into CMs (Gassanov et al., 2008a) . It has also been shown that OT-induced differentiation of EC P19 stem cells into CMs is inhibited by the NOS inhibitor N(G)-nitro-L-arginine methyl ester (L-NAME). The NO donor S-nitroso-N-acetylpenicillamine (SNAP) was able to reverse L-NAMEmediated inhibition of EC P19 cell differentiation into CMs . This study clearly indicates a role for NO and NOS enzymes in stem cell differentiation, but it is evident that thjis may be a complex process. This complexity is highlighted by the fact that suppression of NOS activity by L-NAME has also been shown to increase the number of stem and progenitor cells differentiating into CMs . Another study has reported that exposure of D3 stem cells to AVP increases the number of beating embryoid bodies and also heightens GATA-4 expression. These AVP effects on the cells were also found to be antagonized by L-NAME , again suggesting a positive role for NO in stem cell differentiation into CMs. This investigation highlighted the expression of AVP receptors in undifferentiated D3 cells, with the expression profile changing during the differentiation process . It has been observed in the EC P19 cell model that AVP not only increases spontaneously-occurring cardiomyogenesis but also initiates the process Gutkowska et al., 2007) . The OTR-NO-cGMP pathway that is essential for OT-elicited differentiation of EC P19 stem cells into CMs is associated with elevation of GATA-4 and myocyte enhancer factor 2c (MEF2c) . GATA-4 regulates the expression of genes that are critical for CM differentiation. MEF2c is a member of the MEF2 family that is involved in cardiac, skeletal, and smooth muscle development. Partial GATA-4 gene targeting in cardiac and non-cardiac cells indicates that even modest variations in GATA-4 gene level or activity can play a role in the maintenance of normal cardiac function (Bisping et al., 2006) . GATA-4 has also been implicated in intercellular cross-talk by inducing hypertrophy-associated angiogenesis via vascular endothelial growth factor (VEGF) release and targeting the endothelium (Heineke et al., 2007) . The upstream sequence of OTR contains putative binding sites for GATA-4 and Nkx2.5 and GATA-4 also serves as a key transcriptional regulator of numerous cardiac peptides, including ANP, BNP and OTR (Uchida et al., 2007) . GATA-4 has also been identified in stem and progenitor cells of the heart in combination with OT-mediated CM differentiation (Matsuura et al., 2004; Oyama et al., 2007) . A recent study has demonstrated that undifferentiated murine ES cells express BNP and its receptors, with its signaling being essential for cell survival and clonal growth (Abdelalim & Tooyama, 2009) . This observation suggests possible interaction of the OT and NP systems in ES cells during cardiomyogenesis.
Differentiation of endogenous stem cells isolated from animal hearts
The idea that OT has cardio-regenerative capacities is supported by the observation that this hormone induces the differentiation of cultured mice (Matsuura et al., 2004) and rats (Oyama et al., 2007) resident cardiac stem cells (CSCs). In the adult heart, CSCs maintain a balance of survival, proliferation and self-renewal to replace mature cells that are lost during injury or turnover. Matsuura's group revealed the presence of a Sca-1 + stem cell population in adult mouse hearts expressing telomerase reverse transcriptase, which has been associated with self-renewal potential (Matsuura et al., 2004) . These cells, lacking hematopoietic markers, are easily distinguished from hematopoietic stem cells of bone marrow origin, and when treated with OT, differentiate into functional CMs. Although the cells present the early cardiac markers GATA-4 and MEF2, they do not express Nkx-2.5 or genes encoding cardiac sarcomeric proteins. When exposed to OT, a small population of Sca-1 + cells manifest sarcomeric structures and form spontaneously-beating CMs. In addition, after intravenous delivery, Sca-1+ cardiac stem cells can be recruited to the myocardium injured by ischemia/reperfusion and can functionally differentiate in situ (Matsuura et al., 2004) . Importantly, these cells had positive ionotropic responses to isoproterenol via 1-adrenergic receptor signaling. Given the apparently small number of CMs generated in vitro by OT stimulation, this raises the questionof whether or not OTmediated cardiomyogenesis is a default pathway for CSCs. Accordingly, Matsuura et al. reported that OT induces about 0.5-1% of Sca-1 POS ckit NEG CD45 NEG cells from the adult murine heart to differentiate into functional, spontaneously-beating immature CMs (Matsuura, et al., 2004) . In this regard, the cardiac differentiation of Sca-1+ cells does not require cell aggregation for the process to proceed (Matsuura, et al., 2004) . On the other hand, a study by the same group in another (CSC) type isolated from the rat heart (Oyama, et al., 2007) disclosed that OT treatment resulted in the generation of 5% CMs. These cells, termed cardiac side population cells (CSPs), but not to corresponding side population cells isolated from bone marrow, differentiated into CMs in response to OT treatment. Therefore, OT possesses more powerful cardiogenic activity against CSCs than previously reported. CSPs have the ability to efflux Hoechst dye, a process dependent on ABC transporters. CSCs, especially Abcg2-dependent CSPs, have been associated with stem/progenitor cells. These cells are positive for Abcg2, Sca-1, ckit (low), CD34 (low), CD45 (low) and negative for CD31 Pfister et al., 2005) . A possible role for CSCs in heart healing is indicated by increased numbers of Abcg2-expressing cells in the border zone adjacent to myocardial infarcts . Stimulation of CM differentiation could be concomitant with neovascularization because OT stimulates endothelial cell growth (Thibonnier et al., 1999) and angiogenesis (Cattaneo et al., 2008) .
OT mediates cardioprotection
The absence of either OT or its receptors in knockout mice, however, has not been reported to produce cardiac insufficiencies Takayanagi et al., 2008) . Although OT knockout mice have a normal heart structure, experiments have shown augmented intrinsic heart rates in these animals, indicating that an intracardiac OT system controls cardiac electrical activity (Bernatova et al., 2003) . Although the pathophysiological role of OT is beginning to be understood, accumulating evidence indicates multiple beneficial effects in the heart and vasculature. To date, OT's cardiovascular properties include: i. natriuresis (Soares et al., 1999) and decreased blood pressure (BP), possibly secondary to atrial natriuretic peptide (ANP) release Petersson, 2002a) ii. negative inotropic and chronotropic effects Ondrejcakova et al., 2009 ) and parasympathetic neuromodulation (Mukaddam-Daher et al., 2001) ; iii. vasodilatation via the OTR-induced NO pathway; iv. endothelial cell growth and possible vessel generation (Cattaneo et al., 2008; Cattaneo et al., 2009; Thibonnier et al., 1999) ; and v. modulation of insulin release (Sirotkin et al., 2003) and anti-diabetic actions (Florian, et al., 2010) . At the cellular level, protective OT: i. has antioxidant properties (Iseri et al., 2005a (Iseri et al., , 2005b ii. has anti-inflammatory actions (Jankowski et al., 2010a; Szeto et al., 2008) , iii. potentiates glucose uptake in neonatal and adult CMs exposed to hypoxia and conditions of insulin resistance mimicked by the presence of ketone bodies (Florian, et al., 2010) iv. stimulates endothelial markers in mesenchymal cells (Kim et al., 2010) and stem cells isolated from the heart as a side population (Oyama et al., 2007) . Central, intraventricular infusion of OT is accompanied by an increase in blood pressure; this effect is probably associated with the stimulation of substance P forebrain receptors by OT (McCann et al., 2002 ). OT's ability to raise blood pressure is caused not only by its vasoconstrictory activity but also by antidiuretic activity. Peripheral administration of OT, on the contrary, lowers the average arterial pressure in rats and does not affect heart rate (Petersson, 2002a) . On the other hand, in the absence of a central regulatory influence, OT can bring down the heart rate and reduce the strength of contractions of isolated atria during perfusion of rat hearts Mukaddam-Daher et al., 2001 ). In addition, intracardiac OT stimulating the release of ANP may control cardiovascular homeostasis and the body's internal environment Gutkowska et al., 1997 ). OT's negative chronotropic action was recently associated with attenuation of cardiac damage evinced by ischemia-reperfusion (Ondrejcakova et al., 2009) . Positive cardiac effects can also be attributed to the fact that OT stimulates ANP release by improving hydromineral homeostasis as well as cardiac hypertrophy and reducing proinflammatory mediators (Jankowski et al., 2010a) . ANP, a member of the NPs family that includes BNP, C type natriuretic peptide and urodilatin, is released into the circulation after volume expansion, atrial stretch (Dietz, 2005) , hypoxia (Toth et al., 1994) and in response to various hormones and neurotransmitters (Antunes-Rodrigues et al., 1997; McCann et al., 2002) . ANP causes BP to decline with a concomitant increment of diuresis, natriuresis and decrease plasma volume (Christensen, 1993; Ruskoaho, 1992) . NPs also inhibit the sympathetic nervous system and hormones involved in cardiac hypertrophy, such as angiotensin II, endothelin and AVP (Gerstberger et al., 1992; Jankowski, 2009; Kaneko et al., 1988; Mukaddam-Daher et al., 2009; Neuser et al., 993) . NPs signaling via functional receptors (NPR-A and NPR-B) prevents pathological hypertrophy (Oliver et al., 1997) and cardiac fibrosis (Calderone et al., 1998) by attenuating both DNA and collagen synthesis in cardiac fibroblasts, oxidative stress (Baldini et al., 2005; De Vito et al., 2003) and inflammation (Kiemer & Vollmar, 2001 ). Recent reports indicate that BNP and ANP activity is associated with lipolysis and postprandial lipid oxidation (Birkenfeld et al., 2008) . Both hormones modulate fatty acid trafficking and prevent triglyceride accumulation in CMs via cGMP signaling (Khairallah et al., 2008) . The different cardioprotective actions of OT were recently demonstrated in animal models of myocardial infarction (MI). In rat and rabbit models of ischemic heart disease, OT treatment significantly reduced infarct size and improved parameters of heart function (Alizadeh et al., 2010; Houshmand et al., 2009; Jankowski et al., 2010a; Kim et al., 2010; Kobayashi et al., 2009; Ondrejcakova et al., 2009 ).
OT Signaling in cardiovascular system
In cardiac cells, several signaling pathways have also been postulated in conjunction with specific functions in the heart. Figure 1 illustrates the hypothetical pathways in the heart that are associated with OT-mediated cardioprotection, such as the prevention of apoptosis, CM hypertrophy and fibrosis, with stimulation of glucose uptake, cell proliferation and differentiation. OT signaling depends on coupling to specific G-proteins, cell type and localization on the cell membrane surface. As a result, OTR stimulates different second messengers, which consequently exerts various physiological effects (Reversi et al., 2005) . Due to its organ-and tissue-specific expression patterns, it is believed that OTR is regulated largely at the gene transcription level (Devost et al., 2008; Zingg & Laporte, 2003) . In the cardiovascular system, OTR is associated with the ANP-cGMP and NO-cGMP pathways, which reduce the force and rate of contraction and increase vasodilatation. Our recent report shows that OT increases glucose uptake in CMs via phosphoinositide-3-kinase (PI3K) and potentiates the glucose uptake effect of 2,4-dinitrophenol, an uncoupler of oxidative phosphorylation targeting the mitochondria (Florian, et al., 2010) . PI3K pathways are considered beneficial during myocardial injuries (Cantley, 2002; Fujio et al., 2000; Miki et al., 2007) . The calcium-calmodulin kinase kinase (Ca-CAMKK) and AMP-activated protein kinase (AMPK) pathways are also involved in OT-mediated glucose uptake in CMs (Florian et al., 2010) . AMPK activation in the heart after ischemia and reperfusion is recognized as cardioprotective because AMPK limits both apoptosis and cell damage because both limits apoptosis and cell damage (Lee et al., 2008; Miki et al., 2007; Russell et al., 2004) . We should also consider p38 MAPK and extracellular signal-regulated kinase 1/2 (ERK 1/2) phosphorylation which may contribute to OT's proliferative activity (Devost et al., 2008) . More recently, in a rabbit model of myocardial ischemia-reperfusion, OT treatment induced ERK1/2, AKT and eNOS phosphorylation in cardiac tissues (Kobayashi et al., 2009) . Therefore, OT, like other G-protein-coupled ligands, can act by PI3K/AKT activation and projection onto downstream kinases. Recent studies have demonstrated that the cardioprotective effects of OT are mediated through opening the mitochondrial ATPdependent potassium (mitoKATP) channels in the rat heart (Alizadeh et al., 2010) . 
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OT promotes the migration of human dermal EC, breast-derived EC (Cassoni et al., 2006) and human umbilical vein EC (HUVEC) (Cattaneo et al., 2008; Cattaneo et al., 2009 ). The pro-migratory effect of OT requires OTR activation of the phosphatidylinositol-3-kinase (PI3K)/AKT/eNOS pathway (Cattaneo et al., 2009) . Moreover, OT increases proliferation of EC and alters gene expression for adhesion molecules and matrix metalloproteinases (MMPs), contributing to improved cell motility and growth (Cassoni et al., 2006) . Angiogenic and anti-apoptotic OT effect was indicated by increased CD31 + microvessels (Jankowski et al., 2010b) . In this way, OT can control blood flow to the heart.
OT in stem cells therapy
Cardiovascular disease is one of the leading causes of death throughout the world . Following myocardial infarct (MI), endogenous repair mechanisms are insufficient for meaningful regeneration, therefore, muscle lost is replaced by non-contractile fibrotic scar (Laflamme et al., 2007) . Because cardiomyocytes are unable to regenerate in the adult heart, cell-based therapy of transplantation provides a potential alternative approach to replace damaged myocardial tissue and restore cardiac function. A major roadblock toward this goal is the lack of donor cells, therefore, it is urgent to identify the cardiovascular cells that are necessary for achieving cardiac muscle regeneration (Dowell et al., 2003) , to treat heart failure (Dowell et al., 2003; Raeburn et al., 2002) and restore function. (Hassink et al., 2003; Orlic et al., 2002) . Several candidates have been investigated: fetal (Li et al., 1997) and neonatal (Watanabe et al., 1998 ) CM, embryonic stem cells (Min et al., 2002; Min et al., 2003) , cardiac resident stem cells, and skeletal myoblasts (Dimmeler, Zeiher, & Schneider, 2005; Leor et al., 1996; Menasche et al., 2001; Menasche et al., 2003; Murry et al., 1996; Taylor et al., 1998) . Alternative source are the bone marrow-derived stem cells (Dimmeler, et al., 2005) . However, recent studies have questioned the ability of implanted, untreated stem cells to generate new CMs (Laflamme et al., 2007; Murry et al., 2004; Noiseux et al., 2006) . Most cells die within hours of transplantation due to the interplay of ischemia, inflammation, and apoptosis (Menasche, 2009; Rosenzweig, 2006) . Among the cells used, the MSCs are more suitable for the cell therapy because of easy isolation, high expansion potential giving an unlimited pool of transplantable cells, low immunogenicity, amenability to ex vivo genetic modification and multipotency. It has been shown that injection of MSC either, directly into infarcted hearts (Gnecchi & Melo, 2009 ) by intramuscular (Shabbir et al., 2009) or intraperitoneal injections (Takahashi et al., 2006) improves myocardial function and repair. Following exposure to hypoxia and serum starvation, conditions that mimic MI, MSC are stimulated to secrete several growth factors and cytokines (Gnecchi & Melo, 2009 ). The exact mechanisms underlying MSC therapeutic effects require further investigations and challenges remain in optimizing the cultureexpansion conditions, the MSC capacity for growth factor production and conditions to direct stem cells differentiation into CMs or endothelial cells. Recent studies have shown that direct injection with OT-treated MSCs into the rat heart after ischemia-reperfusion injury improves the engraftment rate and results in an enhanced cardio-protective effect via: increased transmigration activity, the upregulation of matrix metalloproteinase-2 mRNA, the integration of MSCs into the myocardium as well as the anti-fibrotic and antiinflammatory effects (Kim et al., 2010) .
We propose that MSCs and other types of the stem cells should be treated with OT before their engraftment in vivo. Based on our preliminary data, we expect that preconditioning with OT will enhance the capacity of these cells to repair infarcted myocardium due to reduced cell death after implantation, increased angiogenic potential, and by enhanced secretion of paracrine factors. Alternatively, the therapeutical potential of these cells can be improved by the introduction of the OT-expressing construct as recently demonstrated (Gassanov et al., 2008a) .
Summary and conclusions
Our research lead to the observation that OT and OTR are synthesized in CMs, and we have identified OT as a potent, naturally-occurring cardiomyogenic factor, which by OTR upregulation promotes the differentiation of embryonic and somatic stem cells residing in the heart to mature and functional CMs. All these OT actions have physiological relevance, particularly on glucose uptake in CMs, since it is reduced in hearts from insulin-resistant diabetic mice, a disturbance that culminates in cardiac dysfunction. Understanding the mechanisms of cardiac differentiation by OT can provide therapeutic approaches to the management of heart diseases. Currently, it is still extremely difficult to obtain new cardiac cells in vitro using stem cells isolated from the heart, as the only method that has provided satisfactory results is limited to co-culture with mature CMs. OT and some OT agonists, such as OT-Gly-Lys-Arg, that do not interfere with other physiological processes in the body (for example, without renal and hemodynamic effects), can successfully stimulate the differentiation of stem cell residing in the heart. In pathological conditions, such as cardiac ischemia and diabetes, this inducer can serve to stimulate the production of cardiac cells lost during the development of these pathologies. The advantage of such a therapy is supported by the fact that OT is produced endogenously in the organism, and does not have significant side effects when administered clinically. Moreover, it is now possible to inject (transplant) stem cells after previous stimulation with OT inducers, as in the case of heart attacks. Alternatively, direct treatment with OT molecules could promote cardiomyogenesis in situ and the regeneration of damaged hearts. 
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